Is Tirzepatide FDA Approved? Mounjaro & Zepbound Status (2026)

Is Tirzepatide FDA Approved? The Short Answer

Yes, tirzepatide is FDA-approved. Eli Lilly markets it under two brand names, each with its own approved use:

• Mounjaro: type 2 diabetes in adults (FDA-approved May 2022).
• Zepbound: chronic weight management in adults (FDA-approved November 8, 2023).
• Zepbound: moderate-to-severe obstructive sleep apnea in adults with obesity (FDA-approved December 20, 2024).

One molecule, three FDA-approved indications, two brand names. The catch most readers miss: this only applies to the branded, FDA-regulated product. Compounded and research-grade tirzepatide is not the FDA-approved finished drug, a distinction covered in detail below.

Tirzepatide FDA Approval Timeline

Tirzepatide (development code LY3298176) is a once-weekly injectable peptide from Eli Lilly. It activates two incretin receptors at once, GLP-1 and GIP, which is what separates it from GLP-1-only drugs. Each FDA approval added a new indication under a specific brand name. Here is how the approvals stacked up.

Mounjaro: type 2 diabetes (May 2022)

The FDA approved Mounjaro (tirzepatide) for adults with type 2 diabetes in May 2022 under NDA 215866. It is indicated as an adjunct to diet and exercise to improve glycemic control. Mounjaro is not approved for type 1 diabetes. This diabetes approval, backed by Eli Lilly's phase 3 clinical trial program, established tirzepatide's safety and efficacy profile and set the stage for the weight management indication that followed.

Zepbound: chronic weight management (November 8, 2023)

On November 8, 2023, the FDA approved Zepbound (tirzepatide) for chronic weight management. Eligible adults are those with a BMI of 30 or higher (obesity), or a BMI of 27 or higher (overweight) with at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, or cardiovascular disease. This made Zepbound the first dual GIP and GLP-1 receptor agonist approved for weight management.

The evidence base was SURMOUNT-1, published in the New England Journal of Medicine in 2022, where participants on the 15 mg dose lost a mean of 20.9 percent of body weight over 72 weeks. Note the brand split: this is the same tirzepatide molecule as Mounjaro, but the weight management indication belongs to Zepbound, not Mounjaro. The Mounjaro vs Zepbound comparison covers why Eli Lilly split the brands.

Zepbound: obstructive sleep apnea (December 20, 2024)

On December 20, 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This was a landmark: the first time the FDA approved any medication specifically for OSA. The mechanism is understood to work primarily through weight reduction, which lessens upper-airway obstruction during sleep. After this approval, Zepbound holds two weight-related indications, while Mounjaro holds neither.

Mounjaro vs Zepbound: Same Drug, Different FDA Indications

"Is Mounjaro FDA-approved for weight loss?" is one of the most searched versions of this question. The short answer is no, and the reason is the brand split. Both products contain identical tirzepatide at identical doses; the FDA approval attaches to the brand-indication pair, not the molecule.

The practical takeaway: if weight management is the goal and there is no type 2 diabetes diagnosis, a prescriber works from the Zepbound label. The full brand-by-brand breakdown lives in the Mounjaro vs Zepbound comparison.

Is Compounded Tirzepatide FDA Approved?

No. Compounded tirzepatide is not an FDA-approved finished drug product. Compounding pharmacies prepare it from bulk tirzepatide, which means it has not gone through FDA review for safety, efficacy, or manufacturing quality the way Mounjaro and Zepbound have. Only the branded, Eli Lilly-manufactured product carries FDA approval. The FDA has issued direct safety communications warning about unapproved GLP-1 drugs used for weight loss.

The legal picture tightened after the FDA removed tirzepatide from its drug shortage list in October 2024, which narrowed the legal basis for large-scale compounding. Enforcement and proposed rulemaking have continued to restrict bulk compounding since then. Court activity has at times allowed some compounders to continue temporarily, but the window has been closing. For the current legal status, pricing, and sourcing risks, read the compounded tirzepatide guide.

For cross-compound context: retatrutide is not FDA-approved at all, unlike tirzepatide. Different molecule, different regulatory status.

Who Can Get FDA-Approved Tirzepatide?

Eligibility differs by brand because each brand carries a different FDA-approved indication. A prescriber determines clinical appropriateness in every case.

Eligibility for Mounjaro (type 2 diabetes)

• A type 2 diabetes diagnosis (Mounjaro is not approved for type 1 diabetes).
• Prescribed as an adjunct to diet and exercise to improve glycemic control.
• Requires a prescription; insurance prior authorization is often needed.

Eligibility for Zepbound (weight management)

• A BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition.
• Accepted comorbidities include type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, and cardiovascular disease.
• Adults aged 18 and older.

Eligibility for Zepbound (sleep apnea)

• Moderate-to-severe obstructive sleep apnea in adults with obesity.
• This specific OSA indication can support coverage pathways that an obesity-only prescription may not, including some Medicare Part D plans.

Off-Label Uses and What Is Being Studied

As of 2026, tirzepatide's FDA-approved uses are the three already covered: type 2 diabetes (Mounjaro) plus chronic weight management and obstructive sleep apnea (Zepbound). Anything beyond that is either off-label or still under investigation.

• No FDA cardiovascular indication. Tirzepatide does not carry an FDA-approved cardiovascular risk-reduction indication. Semaglutide received one in 2024; tirzepatide has not as of 2026.
• Under study, not approved. Tirzepatide is being studied in trials for conditions including heart failure and metabolic liver disease. None of these have FDA approval as of 2026, and none should be treated as an available indication.
• Off-label prescribing exists. A clinician may prescribe an FDA-approved drug off-label at their discretion, but off-label use is not the same as an FDA-approved indication.

For the mechanism behind these effects, the what is tirzepatide explainer covers the dual GIP and GLP-1 pharmacology in depth.

Where to Get FDA-Approved Tirzepatide

FDA-approved tirzepatide means the branded product, Mounjaro or Zepbound, from a licensed pharmacy with a valid prescription.

• Licensed pharmacies: Mounjaro and Zepbound are dispensed by prescription at standard pharmacies.
• LillyDirect: Eli Lilly's self-pay program offers Zepbound single-dose vials, with lower-dose vials priced around 399 dollars per month at the time of writing.
• Telehealth platforms: some can prescribe, but confirm they supply the FDA-approved brand-name product rather than a compounded version.
• Insurance coverage varies. The Zepbound OSA indication can support coverage pathways, including some Medicare Part D plans, that an obesity-only prescription would not.

Cost detail by brand sits in the tirzepatide cost guide, and the compounded vs brand tradeoff is in the compounded tirzepatide guide.

Watch: Zepbound and tirzepatide explained by a physician

Dr. Melody Covington, a board-certified physician, walks through the Zepbound and tirzepatide FDA approval, how it works, and the weight loss data in a focused overview.

Frequently asked questions

References

1. U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. FDA News Release. November 8, 2023. [FDA.gov]
2. U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. NDA 215866. Silver Spring, MD: FDA; May 2022. [FDA label PDF]
3. U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. FDA News Release. December 20, 2024. [FDA.gov]
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. [PubMed]
5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393:26-36. doi:10.1056/NEJMoa2416394. [NEJM]
6. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA Drug Safety Communication. February 4, 2026. [FDA.gov]

Related tirzepatide articles